Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis - PubMed (original) (raw)

Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis

Suzhen Dong et al. Transl Neurodegener. 2012.

Abstract

Alzheimer's disease (AD) is a common neurodegenerative disease characterized clinically by progressive deterioration of memory, and pathologically by histopathological changes including extracellular deposits of amyloid-beta (A-beta) peptides forming senile plaques (SP) and the intracellular neurofibrillary tangles (NFT) of hyperphosphorylated tau in the brain. This review focused on the new developments of amyloid cascade hypothesis with details on the production, metabolism and clearance of A-beta, and the key roles of some important A-beta-related genes in the pathological processes of AD. The most recent research advances in genetics, neuropathology and pathogenesis of the disease were also discussed.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Aβ and Aβ-related genes in AD. Aβ is produced by sequential cleavage of APP by β-secretase (BACE1) and γ-secretase. γ-secretase is a multi-protein complex, of which PS1 or PS2 is the catalytic core. After being produced, Aβ is secreted outside the cell and binds to various isoforms of ApoE. These Aβ-binding ApoE isoforms will allow Aβ to undergo metabolism in different pathways, e.g., clearance via BBB, degradation by Aβ-degradating enzymes (IDE or neprilysin), deposition or trafficking into the cell. The affinity of ApoE4 to Aβ is lower than that of ApoE2 or ApoE3. While ApoE2 and ApoE3 help Aβ to be cleared by transport or degradation, ApoE4 mainly induce Aβ to aggregation, implicating it to be a high risk factor for AD. There is a feedback existing in vivo to keep proper Aβ levels. When Aβ is generated, AICD is released, which is translocated into the nucleus and initiates the transcription of neprilysin. Increased neprilysin protein will degradate Aβ and hereby reduces Aβ to a proper level.

References

    1. Möller HJ, Graeber MB. The case described by Alois Alzheimer in 1911. Eur Arch Psychiatry Clin Neurosci. 1998;248:111–122. - PubMed
    1. Mount C, Downton C. Alzheimer disease: progress or profit? Nat Med. 2006;12:780–784. - PubMed
    1. Bachman DL, Wolf PA, Linn RT, Knoefel JE, Cobb JL, Belanger AJ, White LR, D’Agostino RB. Incidence of dementia and probable Alzheimer’s disease in a general population: the Framingham Study. Neurology. 1993;43:515–519. - PubMed
    1. Hardy J. The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc Natl Acad Sci USA. 1997;94:2095–2097. - PMC - PubMed
    1. Small GW. The pathogenesis of Alzheimer’s disease. J Clin Psychiatry. 1998;59(Suppl 9):7–14. - PubMed

LinkOut - more resources